InsiderSignal.AI

InsiderSignal.ai

ATYR - Atyr Pharma Inc

Insider Purchase by Schimmel Paul (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

4 months ago, Schimmel Paul, serving as Dir at Atyr Pharma Inc (ATYR), purchased 1,000,000 shares at $0.91 per share, for a total transaction value of $911,801.00. Following this transaction, Schimmel Paul now holds 2,101,056 shares of ATYR.

This purchase represents a 91.00% increase in Schimmel Paul's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, October 8, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, October 9, 2025, 1 day after the trade was made.

Atyr Pharma Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Schimmel Paul

Dir

Paul Schimmel, Ph.D. is an independent director of aTyr Pharma Inc. (ATYR), a position he has held since September 2005, and a scientific founder of the company.[[1]](https://fintool.com/app/research/companies/ATYR/people/paul-schimmel)[[2]](https://en.wikipedia.org/wiki/ATyr_Pharma) Aged 84, he recently engaged in insider trading at ATYR as a director and beneficially owns 1,123,819 shares (1.26%).[[1]](https://fintool.com/app/research/companies/ATYR/people/paul-schimmel) Schimmel is a Professor of Molecular Medicine and Chemistry at Scripps Research, previously the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics at MIT.[[1]](https://fintool.com/app/research/companies/ATYR/people/paul-schimmel) He earned a B.A. from Ohio Wesleyan University and a Ph.D. in biochemistry and biophysics from MIT.[[1]](https://fintool.com/app/research/companies/ATYR/people/paul-schimmel) An elected member of the National Academy of Sciences, National Academy of Medicine, National Academy of Inventors, American Philosophical Society, and American Academy of Arts and Sciences, he is renowned for expertise in tRNA synthetase biology foundational to aTyr's development.[[1]](https://fintool.com/app/research/companies/ATYR/people/paul-schimmel)[[2]](https://en.wikipedia.org/wiki/ATyr_Pharma) Career highlights include cofounding public biopharma companies such as Repligen, Alkermes, Cubist, Sirtris, and Alnylam, serving as founding director of Momenta, and directing several private companies including Boragen Inc.[[1]](https://fintool.com/app/research/companies/ATYR/people/paul-schimmel)[[3]](https://biography.omicsonline.org/switzerland/alnylam-pharmaceuticals/paul-schimmel-40183)[[4]](https://www.youtube.com/watch?v=8EeNKanGl_0)

View full insider profile →

Trade Price

$0.91

Quantity

1,000,000

Total Value

$911,801.00

Shares Owned

2,101,056

Trade Date

Wednesday, October 8, 2025

137 days ago

SEC Filing Date

Thursday, October 9, 2025

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Atyr Pharma Inc

Company Overview

No company information available
View news mentioning ATYR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/693120

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime